Huons Global Co., Ltd. (084110.KQ)
KRW 46750.0
(-0.53%)
KRW 46750.0
(-0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.26 Billion KRW | 92.04% |
| 2022 | 6.9 Billion KRW | -78.45% |
| 2021 | 32.04 Billion KRW | -61.4% |
| 2020 | 83.03 Billion KRW | 1771.33% |
| 2019 | 4.43 Billion KRW | 207.48% |
| 2018 | -4.12 Billion KRW | 80.87% |
| 2017 | -21.57 Billion KRW | 39.3% |
| 2016 | -35.54 Billion KRW | 23.27% |
| 2015 | -46.32 Billion KRW | -346.37% |
| 2014 | -10.37 Billion KRW | -130.91% |
| 2013 | 33.57 Billion KRW | 258.07% |
| 2012 | -21.23 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 8.77 Billion KRW | 146.71% |
| 2024 Q1 | -18.79 Billion KRW | -241.69% |
| 2023 FY | 13.26 Billion KRW | 92.04% |
| 2023 Q3 | -9.74 Billion KRW | 82.29% |
| 2023 Q2 | -55.01 Billion KRW | -603.06% |
| 2023 Q1 | 10.93 Billion KRW | 58.31% |
| 2023 Q4 | 13.26 Billion KRW | 236.18% |
| 2022 Q4 | 6.9 Billion KRW | -94.76% |
| 2022 Q1 | 59.96 Billion KRW | 87.09% |
| 2022 Q2 | 112.69 Billion KRW | 87.95% |
| 2022 Q3 | 131.72 Billion KRW | 16.88% |
| 2022 FY | 6.9 Billion KRW | -78.45% |
| 2021 Q1 | 115.17 Billion KRW | 41.84% |
| 2021 Q2 | 167.28 Billion KRW | 45.24% |
| 2021 Q3 | 92.41 Billion KRW | -44.75% |
| 2021 Q4 | 32.04 Billion KRW | -65.32% |
| 2021 FY | 32.04 Billion KRW | -61.4% |
| 2020 FY | 83.03 Billion KRW | 1771.33% |
| 2020 Q1 | -17.65 Billion KRW | -701.5% |
| 2020 Q3 | 78.9 Billion KRW | 10.55% |
| 2020 Q4 | 81.2 Billion KRW | 2.91% |
| 2020 Q2 | 71.37 Billion KRW | 504.31% |
| 2019 FY | 4.43 Billion KRW | 207.48% |
| 2019 Q2 | 11.02 Billion KRW | 360.87% |
| 2019 Q4 | 2.93 Billion KRW | -57.4% |
| 2019 Q1 | -4.22 Billion KRW | -2.41% |
| 2019 Q3 | 6.89 Billion KRW | -37.53% |
| 2018 Q2 | -2.8 Billion KRW | 86.08% |
| 2018 Q4 | -4.12 Billion KRW | -15933.56% |
| 2018 Q3 | -25.74 Million KRW | 99.08% |
| 2018 Q1 | -20.15 Billion KRW | 7.29% |
| 2018 FY | -4.12 Billion KRW | 80.87% |
| 2017 Q1 | -33.14 Billion KRW | 6.75% |
| 2017 Q2 | -26.23 Billion KRW | 20.84% |
| 2017 Q3 | -18.78 Billion KRW | 28.41% |
| 2017 FY | -21.57 Billion KRW | 39.3% |
| 2017 Q4 | -21.73 Billion KRW | -15.71% |
| 2016 Q1 | -78.44 Billion KRW | -69.33% |
| 2016 FY | -35.54 Billion KRW | 23.27% |
| 2016 Q4 | -35.54 Billion KRW | -11.29% |
| 2016 Q3 | -31.93 Billion KRW | 59.59% |
| 2016 Q2 | -79.03 Billion KRW | -0.76% |
| 2015 FY | -46.32 Billion KRW | -346.37% |
| 2015 Q4 | -46.32 Billion KRW | -20.91% |
| 2015 Q3 | -38.31 Billion KRW | -18.82% |
| 2015 Q2 | -32.24 Billion KRW | -30.19% |
| 2015 Q1 | -24.76 Billion KRW | -138.66% |
| 2014 Q1 | 31.33 Billion KRW | -6.66% |
| 2014 FY | -10.37 Billion KRW | -130.91% |
| 2014 Q3 | 18.78 Billion KRW | -29.18% |
| 2014 Q4 | -10.37 Billion KRW | -155.24% |
| 2014 Q2 | 26.52 Billion KRW | -15.34% |
| 2013 Q2 | 43.03 Billion KRW | -10.69% |
| 2013 Q1 | 48.18 Billion KRW | 326.88% |
| 2013 Q4 | 33.57 Billion KRW | -17.72% |
| 2013 Q3 | 40.8 Billion KRW | -5.18% |
| 2013 FY | 33.57 Billion KRW | 258.07% |
| 2012 FY | -21.23 Billion KRW | 0.0% |
| 2012 Q4 | -21.23 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | 30.042% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | 29.382% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 90.712% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | 69.985% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | 235.174% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 117.106% |
| Boditech Med Inc. | -31.92 Billion KRW | 141.549% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | -171.739% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | 369.031% |
| Huons Co., Ltd. | 73.9 Billion KRW | 82.053% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 119.608% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | 209.788% |